Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Pain. 2018 Feb;159(2):224–238. doi: 10.1097/j.pain.0000000000001106

Figure 9. S1PR1 content after fingolimod administration.

Figure 9.

Representative blots of S1PR1 levels from (A) Naïve and (B) EAE mice. For vehicle and fingolimod-treated mice, 2–3 samples are shown for both S1PR1 and actin. Relative S1PR1 protein expression comparing vehicle to fingolimod-treated mice from naïve (left side) and EAE mice (right side) from (C-D) membrane, (E-F) cytosol and (G-H) total homogenates. Data represent mean ± SEM. *P<0.05 fingolimod compared to MOG35–55–treated animals that received vehicle.

Supplemental Digital Content 1, which demonstrates the lack of difference in responses in vehicle for fingolimod and W146.